Pilot study of the effect of terodiline chloride (Bicor®) in obstructive pulmonary disease
- 25 Downloads
Terodiline chloride, 150 mg daily, was administered to 10 patients with obstructive pulmonary disease, and pulmonary function tests were performed before and during two weeks of therapy. Serious side effects of anticholinergic type developed in two patients who stopped treatment. Two patients were excluded from the trial for other reasons. The remaining six patients showed signs of bronchodilation. Owing to the high incidence of side effects, treatment with more than 75 mg terodiline chloride per day is impracticable.
Key wordsTerodiline obstructive pulmonary disease lung function heart rate side effects bronchodilation
Unable to display preview. Download preview PDF.
- Iravani, J.: Antagonismus zwischen Terodilin (Bicor) und Acetylcholin an der Bronchialmuskulatur der Ratte. In press (1974)Google Scholar
- Lecerof, H., Malmborg, R.O.: Central hemodynamic effects of terodiline in patients with coronary heart disease. Acta med. scand.186 231–234 (1969)Google Scholar
- Nisell, J.: Personal communicationGoogle Scholar
- Pepine, C. J., Wiener, L.: Relationship of anginal symptoms to lung mechanics during myocardial ischemia. Circulation46 863–869 (1972)Google Scholar
- Ulmer, W.T.: Personal communicationGoogle Scholar
- Vessman, J., Strömberg, S.: Determination of terodiline (Bicor®) in serum by gas chromatography and electron capture detection of benzophenone formed by chromic acid oxidation. Acta pharm. suec.6 508–518 (1969)Google Scholar
- Wibell, L.: Some aspects of the treatment of angina pectoris with presentation of terodiline, a new drug. Opusc. med. (Stockh.)13 78 (1968 a)Google Scholar
- Wibell, L.: Terodiline in angina pectoris — a controlled study of a new drug. Acta Soc. Med. upsalien.73 75 (1968 b)Google Scholar